GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody

We recently reported the development of a fully-human, CD3-binding bispecific antibody for immunotherapy of malignant glioma. To translate this therapeutic (hEGFRvIII-CD3- bi-scFv) to clinical trials and to help further the translation of other similar CD3-binding therapeutics, some of which are ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Gedeon, Patrick C., Streicker, Michael A., Schaller, Teilo H., Archer, Gary E., Jokinen, Micheal P., Sampson, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394377/
https://www.ncbi.nlm.nih.gov/pubmed/32735564
http://dx.doi.org/10.1371/journal.pone.0236374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394377/
https://www.ncbi.nlm.nih.gov/pubmed/32735564
http://dx.doi.org/10.1371/journal.pone.0236374

Ejemplares similares